Literature DB >> 12662119

Pain management in children with sickle cell disease.

Jennifer Stinson1, Basem Naser.   

Abstract

Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. The disease is characterized by chronic hemolytic anemia, as well as acute and chronic complications. One of the most intractable problems encountered by children with SCD is the painful episode that results from tissue ischemia due to vaso-occlusion. Pain related to SCD is unique among pain syndromes due to the unpredictable, recurrent, and often persistent nature of the disease, as well as the recurring and essential need for the use of opioids. Painful vaso-occlusive episodes (VOE) are a principal cause of morbidity and account for a significant number of emergency department and hospital admissions. When untreated or inadequately managed, the pain of VOE may cause both short- and long-term consequences. Despite the fact that pain is an almost universal feature of the disease, children with SCD may form one of the most undertreated and understudied populations. One of the factors contributing to poor pain management is conflicting perceptions between patients, their families, and healthcare professionals about pain that is reported and analgesia that is required. Pain management guidelines have recently been published in an effort to overcome barriers in the assessment and management of pain related to SCD. Although there is considerable variability in the way SCD pain is managed, the standard treatment protocol for painful episodes has been rest, rehydration, and analgesia. However, pain control for children with SCD is often a difficult and complex process, and one that requires frequent systematic pain assessments and continuous adjustment of comfort measures, especially analgesics. There are a variety of analgesic agents to choose from, such as acetaminophen (paracetamol), oral or parenteral nonsteroidal anti-inflammatory drugs, and oral or parenteral opioids. Each of these options has advantages and disadvantages to their use. Continuous infusions of analgesics and patient controlled analgesia have been shown to be effective and widely used in hospital settings to manage severe pain. However, the opioid dose required to achieve pain relief varies considerably within each painful episode, from one episode to another, and between individual patients. Although not yet curable in humans, pain related to SCD can be effectively managed in most patients by using a comprehensive approach that incorporates pharmacologic, psychologic, behavioral, and physical pain management strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12662119     DOI: 10.2165/00128072-200305040-00003

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  53 in total

1.  Low frequency of meperidine-associated seizures in sickle cell disease.

Authors:  S Z Nadvi; S Sarnaik; Y Ravindranath
Journal:  Clin Pediatr (Phila)       Date:  1999-08       Impact factor: 1.168

2.  Assessment of sickle cell pain in children and young adults using the adolescent pediatric pain tool.

Authors:  Linda S Franck; Marsha Treadwell; Eufemia Jacob; Elliott Vichinsky
Journal:  J Pain Symptom Manage       Date:  2002-02       Impact factor: 3.612

3.  Opioid pseudoaddiction--an iatrogenic syndrome.

Authors:  D E Weissman; J D Haddox
Journal:  Pain       Date:  1989-03       Impact factor: 6.961

4.  Safety of intravenous ketorolac therapy in children and cost savings with a unit dosing system.

Authors:  C S Houck; R T Wilder; J S McDermott; N F Sethna; C B Berde
Journal:  J Pediatr       Date:  1996-08       Impact factor: 4.406

5.  Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis.

Authors:  W E Hardwick; T G Givens; K W Monroe; W D King; D Lawley
Journal:  Pediatr Emerg Care       Date:  1999-06       Impact factor: 1.454

Review 6.  A review of evidence about factors affecting quality of pain management in sickle cell disease.

Authors:  J Elander; K Midence
Journal:  Clin J Pain       Date:  1996-09       Impact factor: 3.442

7.  Resolving conflicts: misconceptions and myths in the care of the patient with sickle cell disease.

Authors:  M Sutton; G F Atweh; T D Cashman; W T Davis
Journal:  Mt Sinai J Med       Date:  1999-09

8.  Pain intensity and home pain management of children with sickle cell disease.

Authors:  R L Conner-Warren
Journal:  Issues Compr Pediatr Nurs       Date:  1996 Jul-Sep

9.  High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease.

Authors:  T C Griffin; D McIntire; G R Buchanan
Journal:  N Engl J Med       Date:  1994-03-17       Impact factor: 91.245

10.  Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation.

Authors:  I C Robieux; J D Kellner; M J Coppes; D Shaw; E Brown; C Good; H O'Brodovich; D Manson; N F Olivieri; A Zipursky
Journal:  Pediatr Hematol Oncol       Date:  1992 Oct-Dec       Impact factor: 1.969

View more
  10 in total

1.  HLA class II haplotypes distinctly associated with vaso-occlusion in children with sickle cell disease.

Authors:  Najat Mahdi; Khadija Al-Ola; Abeer M Al-Subaie; Muhallab E Ali; Zaid Al-Irhayim; A Qader Al-Irhayim; Wassim Y Almawi
Journal:  Clin Vaccine Immunol       Date:  2008-02-13

2.  Feasibility and Acceptability of Internet-delivered Cognitive Behavioral Therapy for Chronic Pain in Adolescents With Sickle Cell Disease and Their Parents.

Authors:  Tonya M Palermo; Joanne Dudeney; James P Santanelli; Alexie Carletti; William T Zempsky
Journal:  J Pediatr Hematol Oncol       Date:  2018-03       Impact factor: 1.289

3.  Clinically meaningful measurement of pain in children with sickle cell disease.

Authors:  Matthew P Myrvik; Amanda M Brandow; Amy L Drendel; Ke Yan; Raymond G Hoffmann; Julie A Panepinto
Journal:  Pediatr Blood Cancer       Date:  2013-06-17       Impact factor: 3.167

4.  Endothelin-1 induced desensitization in primary afferent neurons.

Authors:  Terika P Smith; Sherika N Smith; Sarah M Sweitzer
Journal:  Neurosci Lett       Date:  2014-09-08       Impact factor: 3.046

5.  Asthma in sickle cell disease: implications for treatment.

Authors:  Kathryn Blake; John Lima
Journal:  Anemia       Date:  2011-03-03

6.  Mechanisms of pain in sickle cell disease.

Authors:  Kensuke Takaoka; Asha Caroline Cyril; Sandhya Jinesh; Rajan Radhakrishnan
Journal:  Br J Pain       Date:  2020-05-22

7.  Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease.

Authors:  Sudipta Pal; Ruchita Dixit; Soe Moe; Myron Anthony Godinho; Adinegara Bl Abas; Samir K Ballas; Shanker Ram; Uduman Ali M Yousuf
Journal:  Cochrane Database Syst Rev       Date:  2020-03-03

8.  Intravenous Acetaminophen For the Management of Pain During Vaso-occlusive Crises in Pediatric Patients.

Authors:  Paula Baichoo; Arsenia Asuncion; Gladys El-Chaar
Journal:  P T       Date:  2019-01

9.  Sickle cell disease: management options and challenges in developing countries.

Authors:  Daniel Ansong; Alex Osei Akoto; Delaena Ocloo; Kwaku Ohene-Frempong
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-11-04       Impact factor: 2.576

10.  Prescription audit in a paediatric sickle cell clinic in South-West Nigeria: A cross-sectional retrospective study.

Authors:  Fadare Joseph Olusesan; Olatunya Oladele Simeon; Ogundare Ezra Olatunde; Oluwayemi Isaac Oludare; Agaja Oyinkansola Tolulope
Journal:  Malawi Med J       Date:  2017-12       Impact factor: 0.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.